Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter Hanlon

Showing results (61-70 of 90) with videos related to

Pageof 9
Sort By:
BMC Medicine|November 13, 2019
Representation of people with comorbidity and multimorbidity in clinical trials of novel drug therapies: an individual-level participant data analysisPeter Hanlon, Laurie Hannigan, Jesus Rodriguez-Perez, et al.
Age and Ageing|April 29, 2021
Impact of COVID-19 on care-home mortality and life expectancy in ScotlandJennifer K Burton, Martin Reid, Ciara Gribben, et al.
Wellcome Open Research|August 5, 2022
Self-management interventions for Type 2 Diabetes: systematic review protocol focusing on patient workload and capacity supportPeter Hanlon, Iona Bryson, Holly Morrison, et al.
BMC Medicine|October 28, 2022
Assessing trial representativeness using serious adverse events: an observational analysis using aggregate and individual-level data from clinical trials and routine healthcare dataPeter Hanlon, Elaine Butterly, Anoop S V Shah, et al.
British Journal of Cancer|October 25, 2023
Personalised lung cancer risk stratification and lung cancer screening: do general practice electronic medical records have a role?Bhautesh Dinesh Jani, Michael K Sullivan, Peter Hanlon, et al.
Diabetic Medicine : a Journal of the British Diabetic Association|November 28, 2025
Polypharmacy and potentially inappropriate prescribing in people with type 2 diabetes: An analysis of the Scottish Diabetes Research Network national diabetes cohortWilliam Berthon, Stuart J McGurnaghan, Luke A K Blackbourn, et al.
BMC Medicine|November 19, 2021
Hospitalisation events in people with chronic kidney disease as a component of multimorbidity: parallel cohort studies in research and routine care settingsMichael K Sullivan, Bhautesh Dinesh Jani, Alex McConnachie, et al.
BMC Medicine|November 2, 2022
The presence and impact of multimorbidity clusters on adverse outcomes across the spectrum of kidney functionMichael K Sullivan, Juan-Jesus Carrero, Bhautesh Dinesh Jani, et al.
BMJ Medicine|March 20, 2023
Effect of age, sex, and morbidity count on trial attrition: meta-analysis of individual participant level data from phase 3/4 industry funded clinical trialsJennifer S Lees, Peter Hanlon, Elaine W Butterly, et al.
BMJ Medicine|May 13, 2024
Participant characteristics and exclusion from phase 3/4 industry funded trials of chronic medical conditions: meta-analysis of individual participant level dataJennifer Lees, Jamie Crowther, Peter Hanlon, et al.
Pageof 9

Showing results (61-70 of 90) with videos related to

Sort By:
Pageof 9
BMC Medicine|November 13, 2019
Representation of people with comorbidity and multimorbidity in clinical trials of novel drug therapies: an individual-level participant data analysisPeter Hanlon, Laurie Hannigan, Jesus Rodriguez-Perez, et al.
Age and Ageing|April 29, 2021
Impact of COVID-19 on care-home mortality and life expectancy in ScotlandJennifer K Burton, Martin Reid, Ciara Gribben, et al.
Wellcome Open Research|August 5, 2022
Self-management interventions for Type 2 Diabetes: systematic review protocol focusing on patient workload and capacity supportPeter Hanlon, Iona Bryson, Holly Morrison, et al.
BMC Medicine|October 28, 2022
Assessing trial representativeness using serious adverse events: an observational analysis using aggregate and individual-level data from clinical trials and routine healthcare dataPeter Hanlon, Elaine Butterly, Anoop S V Shah, et al.
British Journal of Cancer|October 25, 2023
Personalised lung cancer risk stratification and lung cancer screening: do general practice electronic medical records have a role?Bhautesh Dinesh Jani, Michael K Sullivan, Peter Hanlon, et al.
Diabetic Medicine : a Journal of the British Diabetic Association|November 28, 2025
Polypharmacy and potentially inappropriate prescribing in people with type 2 diabetes: An analysis of the Scottish Diabetes Research Network national diabetes cohortWilliam Berthon, Stuart J McGurnaghan, Luke A K Blackbourn, et al.
BMC Medicine|November 19, 2021
Hospitalisation events in people with chronic kidney disease as a component of multimorbidity: parallel cohort studies in research and routine care settingsMichael K Sullivan, Bhautesh Dinesh Jani, Alex McConnachie, et al.
BMC Medicine|November 2, 2022
The presence and impact of multimorbidity clusters on adverse outcomes across the spectrum of kidney functionMichael K Sullivan, Juan-Jesus Carrero, Bhautesh Dinesh Jani, et al.
BMJ Medicine|March 20, 2023
Effect of age, sex, and morbidity count on trial attrition: meta-analysis of individual participant level data from phase 3/4 industry funded clinical trialsJennifer S Lees, Peter Hanlon, Elaine W Butterly, et al.
BMJ Medicine|May 13, 2024
Participant characteristics and exclusion from phase 3/4 industry funded trials of chronic medical conditions: meta-analysis of individual participant level dataJennifer Lees, Jamie Crowther, Peter Hanlon, et al.
Pageof 9